{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T03:26:42Z","timestamp":1771039602798,"version":"3.50.1"},"reference-count":61,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,2,21]],"date-time":"2019-02-21T00:00:00Z","timestamp":1550707200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Sumitomo Dainippon Pharma Co., Ltd., Japan"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.ymgme.2019.02.005","type":"journal-article","created":{"date-parts":[[2019,2,20]],"date-time":"2019-02-20T02:40:21Z","timestamp":1550630421000},"page":"448-459","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Safety and effectiveness of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: Post-marketing surveillance in Japan"],"prefix":"10.1016","volume":"126","author":[{"given":"Hiroaki","family":"Sasa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Munehiko","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Kino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2019.02.005_bb0005","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","article-title":"Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency","volume":"276","author":"Brady","year":"1967","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2019.02.005_bb0010","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"3733","article-title":"Alpha-galactosidase a deficiency: Fabry disease","author":"Desnick","year":"2001"},{"key":"10.1016\/j.ymgme.2019.02.005_bb0015","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1093\/qjmed\/hcq117","article-title":"Fabry disease: a review of current management strategies","volume":"103","author":"Mehta","year":"2010","journal-title":"Q. J. Med."},{"key":"10.1016\/j.ymgme.2019.02.005_bb0020","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1651-2227.2002.tb03109.x","article-title":"Pain assessment: the advantages of using pain scales in lysosomal storage diseases","volume":"439","author":"Cleeland","year":"2002","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.ymgme.2019.02.005_bb0025","series-title":"Discussion Paper 138","article-title":"A social tariff for EuroQol: results from a UK general population survey","author":"Dolan","year":"1995"},{"key":"10.1016\/j.ymgme.2019.02.005_bb0030","series-title":"Estimating an EQ-5D Population Value Set: The Case of Japan Health Econ","first-page":"341","volume":"11","author":"Tsuchiya","year":"2002"},{"key":"10.1016\/j.ymgme.2019.02.005_bb0035","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised equations for estimated GFR from serum creatinine in Japan","volume":"53","author":"Matsuo","year":"2009","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ymgme.2019.02.005_bb0040","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0002-9149(86)90771-X","article-title":"Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings","volume":"57","author":"Devereux","year":"1986","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ymgme.2019.02.005_bb0045","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.echo.2005.10.005","volume":"18","author":"Lang","year":"2005","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"10.1016\/j.ymgme.2019.02.005_bb0050","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0002-9149(76)90491-4","article-title":"Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence or absence of asynergy","volume":"37","author":"Teichholz","year":"1976","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ymgme.2019.02.005_bb0055","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry outcome survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur. J. Clin. Investig."},{"key":"10.1016\/j.ymgme.2019.02.005_bb0060","author":"European Medicines Agency"},{"key":"10.1016\/j.ymgme.2019.02.005_bb0065","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ymgme.2010.11.155","article-title":"Expert opinion on temporary treatment recommendations for Fabry disease during the shortage of enzyme replacement therapy (ERT)","volume":"102","author":"Linthorst","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2019.02.005_bb0070","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1093\/ndt\/gfp031","article-title":"Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy","volume":"24","author":"Schiffmann","year":"2009","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2019.02.005_bb0075","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.2215\/CJN.04340510","article-title":"Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry registry","volume":"5","author":"Wanner","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2019.02.005_bb0080","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S0735-1097(02)02380-X","article-title":"Cardiac manifestations of Anderson-Fabry disease in heterozygous females","volume":"40","author":"Kampmann","year":"2002","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ymgme.2019.02.005_bb0085","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/eurheartj\/ehm153","article-title":"Cardiac manifestations of Anderson\u2013Fabry disease: results from the international Fabry outcome survey","volume":"28","author":"Linhart","year":"2007","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ymgme.2019.02.005_bb0090","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijcard.2008.03.007","article-title":"Onset and progression of the Anderson-Fabry disease related cardiomyopathy","volume":"130","author":"Kampmann","year":"2008","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ymgme.2019.02.005_bb0095","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/jmg.38.11.750","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males","volume":"38","author":"MacDermot","year":"2001","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2019.02.005_bb0100","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females","volume":"38","author":"MacDermot","year":"2001","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2019.02.005_bb0105","series-title":"Fabry Disease: Perspectives From 5\u202fYears of FOS","first-page":"155","article-title":"Demographics of FOS \u2013 the Fabry outcome survey","author":"Beck","year":"2006"},{"key":"10.1016\/j.ymgme.2019.02.005_bb0110","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/S0140-6736(09)61493-8","article-title":"Fabry outcome survey investigators, enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data","volume":"374","author":"Mehta","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2019.02.005_bb0115","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1073\/pnas.97.1.365","article-title":"Infusion of \u03b1-galactosidase a reduces tissue globotriaosylceramide storage in patients with Fabry disease","volume":"97","author":"Schiffmann","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.ymgme.2019.02.005_bb0120","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1742-1241.2006.01237.x","article-title":"Clinical results of enzyme replacement therapy in Fabry disease: a comprehensive review of literature","volume":"61","author":"Lidove","year":"2007","journal-title":"Int. J. Clin. Pract."},{"issue":"3","key":"10.1016\/j.ymgme.2019.02.005_bb0125","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ymgme.2008.03.003","article-title":"Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3","volume":"94","author":"Vedder","year":"2008","journal-title":"Mol. Genet. Metab."},{"issue":"10","key":"10.1016\/j.ymgme.2019.02.005_bb0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047805","article-title":"Long-term effect of antibodies against infused alpha-galactosidase a in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome","volume":"7","author":"Rombach","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2019.02.005_bb0135","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.2147\/DDDT.S80928","article-title":"Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease","volume":"9","author":"Gol\u00e1\u0148","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ymgme.2019.02.005_bb0140","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10545-011-9400-y","article-title":"Fabry disease, enzyme replacement therapy and the significance of antibody responses","volume":"35","author":"Deegan","year":"2012","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2019.02.005_bb0145","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ymgme.2012.12.005","article-title":"A revised home treatment algorithmfor Fabry disease: influence of antibody formation","volume":"108","author":"Smid","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2019.02.005_bb0150","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","article-title":"Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta","volume":"66","author":"Linthorst","year":"2004","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymgme.2019.02.005_bb0155","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ymgme.2008.03.008","article-title":"Reduced alpha-Gal A enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease","volume":"94","author":"Ohashi","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2019.02.005_bb0160","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfi152","article-title":"Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting","volume":"21","author":"Schiffmann","year":"2006","journal-title":"Nephrol. Dial. Transplant."},{"issue":"1","key":"10.1016\/j.ymgme.2019.02.005_bb0165","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.bbadis.2010.09.007","article-title":"Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy","volume":"1812","author":"Van Breemen","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymgme.2019.02.005_bb0170","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ymgme.2007.06.013","article-title":"Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy","volume":"92","author":"Ohashi","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2019.02.005_bb0175","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1136\/jmg.2004.025791","article-title":"Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry outcome survey)","volume":"42","author":"Hoffmann","year":"2005","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2019.02.005_bb0180","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.ymgme.2019.02.005_bb0185","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/GIM.0b013e3181a23bec","article-title":"A 4-year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase alfa in 36 women with Fabry disease","volume":"11","author":"Whybra","year":"2009","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2019.02.005_bb0190","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jpeds.2009.11.007","article-title":"Four-year prospective clinical trial of agalsidase alfa in children with Fabry disease","volume":"156","author":"Schiffmann","year":"2010","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2019.02.005_bb0195","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/j.1365-2362.2004.01424.x","article-title":"Fabry disease: overall effects of agalsidase alfa treatment","volume":"34","author":"Beck","year":"2004","journal-title":"Eur. J. Clin. Investig."},{"key":"10.1016\/j.ymgme.2019.02.005_bb0200","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1136\/jmg.2005.036327","article-title":"Natural history of fabry disease in females in the Fabry outcome survey","volume":"43","author":"Deegan","year":"2006","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2019.02.005_bb0205","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1651-2227.2005.tb02112.x","article-title":"Is globotriaosylceramide a useful biomarker in Fabry disease?","volume":"94","author":"Young","year":"2005","journal-title":"Acta Paediatr. Suppl."},{"key":"10.1016\/j.ymgme.2019.02.005_bb0210","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2174\/187152506778520718","article-title":"The role of ceramide trihexoside (globotriaosylceramide) in the diagnosis and follow-up of the efficacy of treatment of Fabry disease: a review of the literature","volume":"4","author":"Bekri","year":"2006","journal-title":"Cardiovasc. Hematol. Agents Med. Chem."},{"issue":"10","key":"10.1016\/j.ymgme.2019.02.005_bb0215","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/gim.2014.28","article-title":"Clinical course of patients with Fabry disease who were switched from agalsidase-\u03b2 to agalsidase-\u03b1","volume":"16","author":"Tsuboi","year":"2014","journal-title":"Genet. Med."},{"issue":"7","key":"10.1016\/j.ymgme.2019.02.005_bb0220","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/sj.ki.5000208","article-title":"Clinical benefit of enzyme replacement therapy in Fabry disease","volume":"69","author":"Breunig","year":"2006","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymgme.2019.02.005_bb0225","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease: a randomized trial","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ymgme.2019.02.005_bb0230","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54\u202fmonths of agalsidase beta therapy in patients with Fabry disease","volume":"18","author":"Germain","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2019.02.005_bb0235","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3109\/08860220903150296","article-title":"Kidney function and 24-hour proteinuria in patients with Fabry disease during 36\u202fmonths of agalsidase alfa enzyme replacement therapy: a Brazilian experience","volume":"31","author":"Thofehrn","year":"2009","journal-title":"Ren. Fail."},{"key":"10.1016\/j.ymgme.2019.02.005_bb0240","doi-asserted-by":"crossref","first-page":"60","DOI":"10.2215\/CJN.03130411","article-title":"The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy","volume":"7","author":"Feriozzi","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2019.02.005_bb0245","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s10545-014-9717-4","article-title":"Long-term effectiveness of enzyme replacement therapy in Fabry disease: results from the NCS-LSD cohort study","volume":"37","author":"Anderson","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2019.02.005_bb0250","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1681\/ASN.2006121400","article-title":"Antiproteinuric therapy and Fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-\u03b2","volume":"18","author":"Tahir","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2019.02.005_bb0255","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/ndt\/gfu273","article-title":"Antiproteinuric effect of add-on paricalcitol in Fabry disease patients: a prospective observational study","volume":"30","author":"Pisani","year":"2015","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2019.02.005_bb0260","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1681\/ASN.2008080870","article-title":"Agalsidase alfa and kidney dysfunction in Fabry disease","volume":"20","author":"West","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2019.02.005_bb0265","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/ndt\/gfr420","article-title":"Renal outcome of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation","volume":"27","author":"Warnock","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2019.02.005_bb0270","first-page":"21","article-title":"Long-termeffectiveness of agalsidase alfa enzyme replacement in Fabry disease: a Fabry Outcome Survey analysis","volume":"3","author":"Beck","year":"2015","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2019.02.005_bb0275","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ymgme.2016.05.009","article-title":"Fabry in the older patient: clinical consequences and possibilities for treatment","volume":"118","author":"Lidove","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2019.02.005_bb0280","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1093\/europace\/eur267","article-title":"Incidence and predictors of anti-bradycardia pacing in patients with Anderson-Fabry disease","volume":"13","author":"O'Mahony","year":"2011","journal-title":"Europace"},{"key":"10.1016\/j.ymgme.2019.02.005_bb0285","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/hrt.2006.104026","article-title":"Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa","volume":"94","author":"Hughes","year":"2008","journal-title":"Heart"},{"key":"10.1016\/j.ymgme.2019.02.005_bb0290","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13023-015-0338-2","article-title":"Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10\u202fyears' treatment","volume":"10","author":"Kampmann","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2019.02.005_bb0295","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment","volume":"119","author":"Weidemann","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ymgme.2019.02.005_bb0300","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.amjcard.2005.11.087","article-title":"Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy","volume":"97","author":"Beer","year":"2006","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ymgme.2019.02.005_bb0305","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ijcme.2016.06.002","article-title":"Myocardial fibrosis pathology in Anderson\u2013Fabry disease: evaluation of autopsy cases in the long- and short-term enzyme replacement therapy, and non-therapy case","volume":"12","author":"Nagano","year":"2016","journal-title":"IJC Metabol. Endocr."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719218306516?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719218306516?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:24:05Z","timestamp":1761089045000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719218306516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S1096719218306516"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2019.02.005","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and effectiveness of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: Post-marketing surveillance in Japan","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2019.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}